Clinical Scorecard: Use of Tranexamic Acid in Oncologic Lower Limb Endoprosthetic Reconstruction: A Retrospective Analysis of 617 Cases

At a Glance

Key Highlights

• TXA reduces blood loss and transfusion rates in orthopedic surgeries.
• Patients with cancer have a ninefold increased risk of venous thromboembolism (VTE).
• Concerns exist regarding TXA's safety in hypercoagulable cancer patients.
• The study included 617 patients, with 166 receiving TXA.
• No significant differences in major preoperative medical comorbidities between TXA and non-TXA groups.

Guideline-Based Recommendations

Diagnosis

• Evaluate patients for oncologic indications prior to endoprosthetic reconstruction.

Management

• Consider TXA administration to reduce blood loss in oncologic surgeries.

Monitoring & Follow-up

• Monitor for thromboembolic complications in patients receiving TXA.

Risks

• Assess the risk of VTE in patients with cancer when using TXA.

Patient & Prescribing Data

617 patients undergoing lower extremity endoprosthetic reconstruction.

TXA was administered in various forms, with no significant differences in demographics or comorbidities between TXA-treated and non-TXA groups.

Clinical Best Practices

• Utilize TXA to minimize blood loss in oncologic surgeries while monitoring for VTE risks.
• Ensure thorough preoperative assessment of patients' thromboembolic history.

Related Resources & Content

• Study on TXA in orthopedic oncology